What Is Retatrutide and when and how to try it?

Retatrutide: What it is, How it Works, And Why It’s Different

Retatrutide is a medication in phase 3 clinical trials being evaluated for approval by the FDA. It has a unique way of working and is a newer part of a class of drugs which includes existing successful GLP-1 therapies such as semaglutide (Ozempic) and tirzepatide (Zepbound).

The currently approved medications in this drug class work by targeting one or two hormone pathways. For example, GLP-1 medications like semaglutide primarily target the GLP-1 receptor, stimulating insulin release and reduced appetite, slowing digestion, and improving control of blood sugar.  Tirzepatide, a newer medication, targets GLP-1 and GIP receptors which add an additional pathway and greater effects.

Zepbound®

Starting at $299

Per month. Weekly injection. Average weight loss is 20% of body weight in 12 months*

Start Now

Retatrutide is a triple hormone receptor agonist (“triple G agonist”) that targets three hormone pathways involved in metabolism: GLP-1, GIP, and glucagon. These hormone systems help to regulate appetite, glucose control, and balance energy. Because of its action on all three pathways, retatrutide is being studied to determine whether it can produce greater effects than the other already approved medications in this class.

What Early Research Shows

In phase 2 studies, higher doses of retatrutide showed weight reductions of up to an average of 24% of total body weight over 48 weeks. The weight loss appeared to increase over time and varied based on the dose. Researchers also observed improvements in blood sugar markers, including HbA1c, which reflects average blood sugar levels over approximately 2 to 3 months, and fasting blood glucose.

Since the conclusion of the phase 2 studies, additional benefits have been identified, but these changes are still being studied. Phase 3 trials are ongoing, with early reports suggesting similar or greater weight loss than was seen in phase 2 studies.

As with other medications in this class, gastrointestinal side effects such as nausea, vomiting, and diarrhea have been reported. Long-term safety, durability of weight loss, and real-world use are still being evaluated.

“It is great to have an additional option for patients who plateau on the highest dose of tirzepatide despite rigorous attention to resistance exercise and nutrition ”  - Dr. Kudzai Dombo

Is Retatrutide Available Yet?

Retatrutide has shown promising results during clinical trials, but it is not available yet for use. Before any drug can be prescribed, it must go through a regulatory review by the FDA. This review evaluates all the clinical data and decides whether the benefits of the medication will outweigh the potential risks.

It is currently in phase 3 clinical trials which are designed to confirm that the drug is safe and effective in larger groups. Approval timelines can be complicated and depend on the results of ongoing studies and the outcome of this review process.

Until all these steps are complete, retatrutide will remain an investigational drug therapy.

What Options Exist Today for Menopause-Related Weight Gain

While these newer types of medications are being studied, there are current and reliable approaches to help with weight maintenance and metabolism during menopause.

Any weight loss strategy works best when combined with healthy daily habits. During menopause, it is important to maintain adequate protein intake to prevent muscle loss and maintain metabolic functioning. Resistance training can help preserve muscle mass, which often declines during midlife. Getting enough sleep helps to regulate appetite and increase insulin sensitivity. Incorporating a balanced healthy diet and regular movement are important parts of wellness during menopause with or without additional weight loss medications.  

Currently, several GLP-1 medications are approved to help regulate appetite and act as a weight loss support in individuals who meet certain criteria.

Hormone changes during menopause can affect weight, and when hormone therapy is used to treat other menopause symptoms like hot flashes or night sweats, sometimes women notice an improvement in weight. However, hormone therapy is not considered a primary weight loss treatment for women in menopause.

There are many components that affect metabolic health during menopause and treatment should be based on each woman’s individual health and medical history.

Questions to Ask Your Doctor About New Weight-Loss Medications

When considering weight loss using a medication, it is important to consider multiple factors. A clinician can help determine whether using medication for weight loss is appropriate based on body weight and medical history. They can also help by discussing what to expect concerning weight improvement and potential side effects. This is also a good time to ask about newer medications and how they compare with currently available options. Considering how a medication fits with lifestyle changes and long-term health goals can help guide decision-making.

Conclusion

Retatrutide represents a promising area of research in weight and metabolic health. However, it is still being studied and is not yet available for routine use. In the meantime, existing strategies and treatments remain the primary options for managing weight during menopause.  Working with a clinician can help determine which approach is most appropriate based on individual health needs.

Frequently Asked Questions

What makes Retatrutide different from existing weight loss medications like semaglutide and tirzepatide?

Retatrutide is a triple hormone receptor agonist, often called a “triple G agonist,” because it targets three distinct metabolic pathways: GLP-1, GIP, and glucagon. In contrast, semaglutide (Ozempic) targets only the GLP-1 receptor, and tirzepatide (Zepbound) targets both GLP-1 and GIP. By acting on all three pathways, retatrutide is being studied to see if it can produce more significant effects on appetite regulation, glucose control, and energy balance than the medications currently approved by the FDA.

What have clinical trials revealed so far regarding the effectiveness and safety of Retatrutide?

Phase 2 clinical studies demonstrated that higher doses of retatrutide led to an average weight reduction of up to 24% of total body weight over a 48-week period. Research also showed improvements in blood sugar markers, such as HbA1c and fasting blood glucose. While phase 3 trials are ongoing to confirm these results in larger groups, reported side effects are similar to other drugs in this class, primarily involving gastrointestinal issues like nausea, vomiting, and diarrhea.

Is Retatrutide currently available for prescription, and what are the alternatives for menopause-related weight gain?

Retatrutide is not yet available for use as it remains an investigational drug undergoing phase 3 clinical trials and regulatory review by the FDA. For those managing weight during menopause, current options include approved GLP-1 medications and healthy lifestyle habits such as resistance training to preserve muscle mass and maintaining adequate protein intake. While hormone therapy is used to treat symptoms like hot flashes and may lead to weight improvements, it is not considered a primary treatment for weight loss.